Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease

Cancer

Volumn 97, Issue 3 SUPPL., 2003, Pages 818-824

  Croucher, Peter I ^a   Shipman, Claire M ^a   Van Camp, Ben ^b   Vanderkerken, Karin ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b FREE UNIVERSITY OF BRUSSELS   (Belgium)

Author keywords

Bisphosphonate; Bone resorption; Multiple myeloma; Osteoclast; Osteoprotegerin; Receptor activator of NF B ligand

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; IBANDRONIC ACID; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PARAPROTEIN; RECOMBINANT OSTEOPROTEGERIN; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

BONE ATROPHY; BONE DENSITY; BONE DESTRUCTION; CANCELLOUS BONE; CELL ACTIVATION; CONFERENCE PAPER; DRUG TARGETING; HUMAN; MULTIPLE MYELOMA; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL;

EID: 0037303261     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11125     Document Type: Conference Paper

References (48)

1. Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomma I, for the Finnish Leukemia Group. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet. 1992;340:1049-1052.
2. McCloskey EV, Spector TD, Eyres KS, et al. The assessment of vertebral deformity - a method for use in population studies and clinical trials. Osteoporos Int. 1993;3:138-147.
3. Valentin-Opran A, Charhon SA, Meunier PJ, Edouard CM, Arlot ME. Quantitative histology of myeloma-induced bone changes. Br J Haematol. 1982;52:601-610.
4. Bataille R, Chappard D, Marcelli C, et al. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest, 1991;88:62-66.
5. Taube T, Beneton MN, McCloskey EV, Rogers S, Greaves M, Kanis JA. Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur J Haematol. 1992;49:192-198.
6. Roux C, Ravaud P, Cohen-Solal M, et al. Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma. Bone. 1994;15:41-49.
7. Bataille R, Chappard D, Basle M. Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: a prospective study of 87 bone biospies. Blood. 1996;87:4762-4769.
8. McCloskey EV, MacLennan ICM, Drayson M, Chapman C, Dunn J, Kanis JA. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. Br J Haematol. 1998;100:317-325.
9. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med. 1996;334:488-493.
10. Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol. 1998;16:593-602.
11. Brincker H, Westin J, Abildgaard N, et al. Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Br J Haematol. 1998;101:280-286.
12. Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer. 2001;91:1191-1200.
13. McCloskey EV, Dunn JA, Kanis JA, MacLennan IC, Drayson MT. Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol. 2001;113:1035-1043.
14. Asosingh K, Radl J, Van Riet I, Van Camp B, Vanderkerken K. The 5TMM series: a useful in vivo mouse model of human multiple myeloma. Hematol J. 2000;1:351-356.
15. Vanderkerken K, Goes E, De Raeve H, Radl J, Van Camp B. Follow-up of bone lesions in an experimental multiple myeloma mouse model: Description of an in vivo technique using radiography dedicated for mammography. Br J Cancer. 1996;73:1463-1465.
16. Croucher PI, Shipman CM, Lippitt J, et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood. 2001;98:3534-3540.
17. Radl J, Croese JW, Zurcher C, et al. Influence of treatment with APD-bisphosphonate on the bone lesions in the mouse 5T2 multiple myeloma. Cancer. 1985;55:1030-1040.
18. Croese JW, Zurcher C, Van den Enden-Vieveen MH, Radl J. Effect of long term treatment with bisphosphonate APD on 5T2 mouse multiple myeloma. In: Radl J, Van Camp B, eds. Monoclonal gammophathies III: Clinical significance and basic mechanisms, vol. 14. Leiden: EURAGE, 1991:199-203.
19. Yaccoby S, Pearce RN, Johnson CL, Barlogie B, Choi Y, Epstein J. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol. 2002;116:278-290.
20. Dallas SL, Garrett IR, Oyajobi BO, et al. Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease. Blood. 1999;93:1697-1706.
21. Cruz JC, Alsina M, Craig F, et al. Ibandronate decreases bone disease development and osteoclast stimulatory activity in an in vivo model of human myeloma. Exp Haematol. 2001; 29:441-447.
22. Croucher P, Hijzen A, Shipman CM, et al. Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma [abstract]. Blood. 2001;98:160a.
23. Bataille R, Chappard D, Basle M. Excessive bone resorption in human plasmacytomas: direct induction by tumor cells in vivo. Br J Haematol. 1995;90:721-724.
24. Mundy GR, Raisz LG, Cooper RA, Schechter GP, Salmon SE. Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Engl J Med. 1974;291:1041-1046.
25. Mundy GR, Luben RA, Raisz LG, Oppenheim JJ, Buell DN. Bone-resorbing activity in supernatants from lymphoid cell lines. N Engl J Med. 1974;290:867-871.
26. Choi SJ, Cruz JC, Craig F, et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood. 2000;96:671-675.
27. Choi SJ, Oba Y, Gazitt Y, et al. Antisense inhibition of macrophage inflammatory protein 1-a blocks bone destruction in a model of myeloma bone disease. J Clin Invest. 2001;108: 1833-1841.
28. Anderson DM, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic cell function. Nature. 1997;390:175-179.
29. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165-176.
30. Suda T, Takahashi N, Martin TJ. Modulation of osteoclast differentiation. Endocr Rev. 1992;13:66-80.
31. Wong BR, Rho J, Arron J, et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem. 1997;272: 25190-25194.
32. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymphnode organogenesis. Nature. 1999;397:315-323.
33. Burgess TL, Qian YX, Kaufman S, et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol. 1999;145:527-538.
34. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89:309-319.
35. Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12:1260-1268.
36. Mizuno A, Amizuka N, Irie K, et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun. 1998;247:610-615.
37. Pearce RN, Sordillo EM, Yaccoby S, et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A. 2001;98:11581-11586.
38. Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow microenvironment. Blood. 2001;98:3527-3533.
39. Roux S, Meignin V, Quillard J, et al. RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma. Br J Haematol. 2002;117:86-92.
40. Shipman CM, Holen I, Lippitt JM, Vandenberghe E, Croucher PI. Tumor cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL [abstract]. Blood 2000;96:1552.
41. Sezer O, Heider U, Jakob C, Eucker J, Possinger K. Human bone marrow myeloma cells express RANKL. J Clin Invest. 2002;20:353-354.
42. Seidel C, Hjertner O, Abildgaard N, et al. Serum osteoprotegerin levels are reduced in patients with multiple myeloma with bone disease. Blood. 2001;98:2269-2271.
43. Oyajobi BO, Garrett IR, Williams PJ, Yoneda T, Anderson DM, Mundy GR. A soluble murine receptor activator of NF-kB-human immunoglobulin fusion protein (RANK.Fc) inhibits bone resorption in a murine model of human multiple myeloma bone disease [abstract]. J Bone Miner Res. 2000;15:S176.
44. Capparelli C, Kostenuik PJ, Morony S, et al. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. Cancer Res. 2000;60: 783-787.
45. Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental metastasis. Cancer Res. 2001;61: 4432-4436.
46. Vanderkerken K, Asosingh K, Van Camp B, Croucher P. Anti-tumor effect of recombinant OPG in the murine 5T33MM model [abstract]. Blood. 2001;98:637a.
47. Doran P, Chen D, Khosla S, Riggs L. Osteoprotegerin gene transfer to control myelomatous skeletal disease in the ARH-77 SCID mouse model [abstract]. Blood. 2000;96: 362a.
48. Greipp P, Facon T, Williams CD, et al. A single subcutaneous dose of an osteoprotegerin (OPG) construct (AMGN-0007) causes a profound and sustained decrease in bone resorption comparable to standard intravenous bisphosphonate in patients with multiple myeloma [abstract]. Blood. 2001;98:775a.